8-(acetoxymethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indole | 131849-03-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 8-(acetoxymethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indole
• 英文别名: 8-(acetoxymethyl)-6,7,8,9-tetrahydropyrido<1,2-a>indole；8-(acetoxymethyl)-6,7,8,9-tetrahydro-pyrido[1,2-a]indole；8-acetoxymethyl-6,7,8,9-tetrahydropyrido[1,2-a]indole；6,7,8,9-tetrahydropyrido[1,2-a]indol-8-ylmethyl acetate
• CAS: 131849-03-1
• 化学式: C₁₅H₁₇NO₂
• 分子量: 243.305
• InChiKey: CTPZDTIWANLKQZ-UHFFFAOYSA-N

物化性质

• 沸点：
  397.7±15.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-(acetoxymethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indole 在 2,4,6-三甲基吡啶 、 ammonium hydroxide 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 97.5h， 生成 3-<6,7,8,9-tetrahydro-8-<(trimethylamino)methyl>pyrido<1,2-a>indol-10-yl>-4-(1-methyl-3-indolyl)-1H-pyrrole-2,5-dione trifluoromethanesulfonate
  参考文献：
  名称：

  Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction

  摘要：

  The protein kinase inhibitor staurosporine has been used to design a series of selective bisindolylmaleimide inhibitors of protein kinase C (PKC). Guided by molecular graphics, conformational restriction of the cationic side chain has led to ATP competitive inhibitors of improved potency and selectivity. Two compounds have been further evaluated and were shown to inhibit PKC of human origin and prevent T-cell activation in a human allogeneic mixed lymphocyte reaction. One of these compounds was orally absorbed in mice and antagonized a phorbol ester induced paw edema in a dose-dependent manner. This compound also selectively inhibited the secondary T-cell mediated response in a developing adjuvant arthritis model in rats and provides evidence for the potential use of PKC inhibitors as therapeutic immunomodulators.

  DOI：

  10.1021/jm00053a003
• 作为产物：
  描述：

  ethyl 6,7-dihydro-9-hydroxypyrido<1,2-a>indole-8-carboxylate 在 吡啶 、 lithium aluminium tetrahydride 、 W-2 Raney nickel 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 18.5h， 生成 8-(acetoxymethyl)-6,7,8,9-tetrahydropyrido[1,2-a]indole
  参考文献：
  名称：

  Dieckmann / ring扩容方法制备四氢吡啶并和四氢氮杂环庚烷-[1,2-a]吲哚

  摘要：

  据报道，一般的Dieckmann /环膨胀方法用于稠合的[1,2-a]吲哚体系。这种方法已允许合成制备一系列有效和选择性的蛋白激酶C抑制剂所需的多种取代系统。

  DOI：

  10.1016/s0040-4020(01)86471-1

文献信息

• 4-\x9b3-indolyl!-1H-pyrrolone
  申请人：Hoffmann-La Roche Inc.

  公开号：US05721245A1

  公开（公告）日：1998-02-24

  A compound of the formula ##STR1## wherein R is hydrogen or hydroxy, R.sup.1 and R.sup.2 taken together are a group of the formula --(CH.sub.2).sub.m -- and R.sup.7 is hydrogen or R.sup.1 and R.sup.7 taken together are a group of the formula --(CH.sub.2).sub.n -- and R.sup.2 is hydrogen; R.sup.3 is an aryl or aromatic heterocyclic group; R.sup.4, R.sup.5 and R.sup.6 each independently are hydrogen, halogen, alkyl, hydroxy, alkoxy, haloalkyl, nitro, amino, acylamino, alkylthio, alkylsulfinyl or alkylsulfonyl; R.sup.8 is a group of the formula --(CH.sub.2).sub.p --R.sup.9 or --(CH.sub.2).sub.q --R.sup.10 ; R.sup.9 is hydrogen, alkylcarbonyl, aminoalkylcarbonyl, cyano, amidino, alkoxycarbonyl, aryloxycarbonyl, alkylsulfonyl, aminocarbonyl or aminothiocarbonyl; R.sup.10 is hydroxy, alkoxy, halogen, amino, monoalkylamino, dialkylamino, trialkylamino, azido, acylamino, alkylsulfonylamino, a 5- or 6-membered saturated nitrogen-containing heterocycle; X and Y are oxygen; Z is CH; m, p and q are, independently, an integer from 0 to 5, and n an integer from 1 to 5, as well as pharmaceutically acceptable salts thereof which are useful in the control of inflammatory, immunological, oncological, bronchopulmonary or cardiovascular disorders.

  公式的化合物，其中R是氢或羟基，R1和R2共同构成组--(CH2)m--，R7是氢或R1和R7共同构成组--( )n--，且R2是氢；R3是一种芳香族或芳香杂环群；R4、R5和R6各自独立地为氢、卤素、烷基、羟基、烷氧基、卤代烷基、硝基、氨基、酰氨基、烷基硫醚、烷基亚磺酰基或烷基磺酰基；R8是组--( )p--R9或--( )q--R10；R9是氢、烷基碳酰基、氨基烷基碳酰基、氰基、脒基、烷氧基碳酰基、芳氧基碳酰基、烷基磺酰基、氨基甲酰基或硫代氨基甲酰基；R10是羟基、烷氧基、卤素、氨基、一烷基胺、二烷基胺、三烷基胺、叠氮基、酰氨基、烷基磺酰氨基、一个5或6成员的饱和含氮杂环；X和Y是氧；Z是CH；m、p和q各自独立地为0到5的整数，n为1到5的整数，以及作为药物可接受的盐，其在控制炎症、免疫、肿瘤、支气管肺或心血管疾病方面是有用的。
• Process for the preparation of 2-substituted and 2,3-disubstituted
  申请人：Hoffmann-La Roche Inc.

  公开号：US05399712A1

  公开（公告）日：1995-03-21

  The invention relates to a process for the manufacture of substituted maleimides of the formula ##STR1## wherein R.sup.1 is alkyl, aryl or heteroaryl and R.sup.2 is hydrogen, alkyl, alkoxycarbonyl, aryl or heteroaryl, by reacting an activated glyoxylate of the formula ##STR2## wherein R.sup.1 has the above significance and X is a leaving atom or group, with an imidate of the formula ##STR3## wherein R.sup.2 has the above significance, R.sup.3 is alkyl, aryl or trialkylsilyl and Y is oxygen or sulfur, in the presence of a base and, after treating the resulting reaction product obtained in which R.sup.2 is hydrogen or alkyl with a strong base, hydrolyzing and dehydrating the resulting hydroxy-pyrrolinone of the formula ##STR4## wherein R.sup.1, R.sup.2, R.sup.3 and Y have the above significance. The substituted maleimides of formula I are pharmacologically active, for example as protein kinase C inhibitors and which a useful, for example, in the treatment and prophylaxis of inflammatory, immunological, bronchopulmonary and cardiovascular disorders, or as antiproliferative agents useful, for example, in the treatment of immune diseases and allergic disorders.

  该发明涉及一种制备式为##STR1##的取代马来酰亚胺的方法，其中R.sup.1是烷基、芳基或杂环芳基，R.sup.2是氢、烷基、烷氧羰基、芳基或杂环芳基，通过将式为##STR2##的活化的甘醇酸酯与式为##STR3##的亚胺在碱存在下反应，其中R.sup.1具有上述含义，X是一个脱离原子或基团，然后处理所得的反应产物，其中R.sup.2是氢或烷基，用强碱处理后，水解和脱水所得的式为##STR4##的羟基吡咯烷酮，其中R.sup.1、R.sup.2、R.sup.3和Y具有上述含义。式I的取代马来酰亚胺在药理学上具有活性，例如作为蛋白激酶C抑制剂，可用于治疗和预防炎症、免疫、支气管肺部和心血管疾病，或作为抗增殖剂，例如用于治疗免疫性疾病和过敏性疾病。
• Benzothiazinone and benzoxazinone compounds
  申请人：Abbott GmbH & Co. KG

  公开号：US07049312B1

  公开（公告）日：2006-05-23

  Q is —N=or CR2 X is S, O or NOR3 Y is —O—, —S—, —SO— or —SO2— R and R1 are each, independently, H, a substituted or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl group R2 is H or a substituent R3 is H, or —C(O)R4 R4 is a substituted or unsubstituted aliphatic or aromatic group n is an integer from 0 to 1 Chemical compounds having structural formula I and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders.

  Q是-N=或CR2 X是S，O或NOR3 Y是-O-，-S-，-SO-或-SO2-R和R1分别是H，一个取代或未取代的脂肪族，芳香族，杂环芳香族或芳基烃基团R2是H或一个取代基R3是H，或-C(O)R4 R4是一个取代或未取代的脂肪族或芳香族团n是从0到1的整数具有结构式I和其生理上可接受的盐的化合物，是丝氨酸/苏氨酸激酶和酪氨酸激酶活性的抑制剂。这些化合物抑制的几种酪氨酸激酶参与血管生成过程。因此，这些化合物可以改善血管生成或内皮细胞过度增殖是因素的疾病状态。这些化合物可用于治疗癌症和过度增殖性疾病。
• Pharmaceutically active compounds
  申请人：ASTRAZENECA AB, a Swedish Corporation

  公开号：US20030134886A1

  公开（公告）日：2003-07-17

  The present invention relates to compounds of formula (I) 1 wherein: Ar 1 or Ar 2 is an optionally substituted indole, and the other group is an optionally substituted aromatic or heteroaromatic group, suitably an optionally substituted bicyclic heteroaromatic group, preferably an optionally substituted indole, X is O or S, R is H, OH, NH 2 , C 1-6 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, and R 1 is H, C 1-6 alkyl, fluoro substituted C 1-6 alkyl, phenyl, benzyl, carboC 1-6 alkoxy, carbobensyloxy, carbohydroxy, carbamoyl, or methyl(N-C 1-6 alkylcarbamoyl) and salts and solvates thereof and solvates of such salts, and the use of such compounds in medical therapies.

  本发明涉及公式(I)的化合物：其中：Ar1或Ar2是可选择取代的吲哚基，而另一组是可选择取代的芳香或杂环芳香基，适宜地是可选择取代的双环杂环芳香基，优选地是可选择取代的吲哚，X是O或S，R是H，OH，NH2，C1-6烷基，羟基C1-6烷基，氨基C1-6烷基，R1是H，C1-6烷基，氟取代的C1-6烷基，苯基，苄基，羧基C1-6烷氧基，羧苯基氧基，羧基羟基，氨基甲酰基，或甲基（N-C1-6烷基）甲酰胺基，以及这些化合物的盐和溶剂合物以及这些盐的溶剂合物的用途。
• Substituierte Pyrrole
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0384349A1

  公开（公告）日：1990-08-29

  Die Pyrrolderivate der Formel worin R¹ bis R⁸, R, X, Y und m die in der Beschreibung angegebene Bedeutung haben, sind therapeutisch aktive Sub­stanzen, insbesondere zur Verwendung als antiinflamma­torisch, immunologisch, onkologisch, bronchopulmonär und kardiovaskulär aktive Substanzen oder als Wirkstoffe in der Behandlung von Asthma oder AIDS. Sie werden hergestellt aus entsprechenden Furandion­derivaten, worin O für =N-R, X und Y steht.

  式中的吡咯衍生物 其中 R¹ 至 R⁸、R、X、Y 和 m 具有说明中给出的含义，是具有治疗活性的物质，特别是可用作抗炎、免疫、肿瘤、支气管和心血管活性物质或治疗哮喘或艾滋病的活性物质。 它们由相应的呋喃二酮衍生物制得，其中 O 代表 =N-R、X 和 Y。